Beliefs about weight and breast cancer: an interview study with high risk women following a 12 month weight loss intervention.
CONCLUSION: Beliefs about weight and breast cancer risk were informed by social networks, media reports and personal experiences of significant others diagnosed with breast cancer. Our study has highlighted common doubts, anxieties and questions and the importance of providing a credible rationale for weight control and weight loss which addresses individual concerns. Counselling and health education material should be tailored to facilitate understanding of both genetic and modifiable risk factors and should do more help individuals to visualise the weight and breast cancer link. PMID: 25648828 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 6, 2015 Category: Cancer & Oncology Authors: Wright CE, Harvie M, Howell A, Evans DG, Hulbert-Williams N, Donnelly LS Tags: Hered Cancer Clin Pract Source Type: research

Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery.
Abstract BackgroundFollicle-stimulating hormone receptor (FSHR) is expressed on the endothelial surface of blood vessels associated with solid tumor periphery, where angiogenesis is known to occur. The correlation between FSHR expression and formation of new peritumoral vessels has not been previously investigated.MethodsWe used immunohistochemical techniques involving specific antibodies to detect FSHR and the endothelial markers (CD34, VEGFR2, and D2-40) in tissue samples from 83 patients with lymph node-negative, invasive breast cancer representing four main clinical treatment groups: HR+/HER2-, HR+/HER2+, HR-/...
Source: Clinical Breast Cancer - February 5, 2015 Category: Cancer & Oncology Authors: Planeix F, Siraj MA, Bidard FC, Robin B, Pichon C, Sastre-Garau X, Antoine M, Ghinea N Tags: J Exp Clin Cancer Res Source Type: research

Mechanisms of hormonal therapy resistance in breast cancer.
Abstract Whilst estrogen receptor (ER)-positive breast cancers are preferentially treated with hormone therapy, approximately one-third of them relapse. The mechanisms of refractoriness have been investigated by numerous studies but have not been fully clarified. Hormonal therapy resistance, particularly aromatase inhibitor (AI) resistance, may be related to the acquisition of alternative intracellular ER signaling. We have been investing the mechanisms using cancer specimens and cell lines by monitoring the transcription activity of ERs. AI refractory specimens showed diverse ER activity in the adenovirus estroge...
Source: Clinical Breast Cancer - February 5, 2015 Category: Cancer & Oncology Authors: Hayashi SI, Kimura M Tags: Int J Clin Oncol Source Type: research

Ras suppressor-1 promotes apoptosis in breast cancer cells by inhibiting PINCH-1 and activating p53-upregulated-modulator of apoptosis (PUMA); verification from metastatic breast cancer human samples.
Abstract Metastasis, responsible for most deaths from breast cancer (BC), is a multistep process leading to cancer cell spread. Extracellular matrix (ECM)-related adhesion and apoptosis resistance play pivotal role in metastasis. Ras suppressor-1 (RSU-1) localizes to cell-ECM adhesions and binds to pro-survival adhesion protein PINCH-1. Little is known about the role of RSU-1 in BC. In the present study, we investigated the role of RSU-1 in BC metastasis using two BC cell lines that differ in terms of their metastatic potential and a set of 32 human BC samples from patients with or without lymph node metastasis. W...
Source: Clinical Breast Cancer - February 3, 2015 Category: Cancer & Oncology Authors: Giotopoulou N, Valiakou V, Papanikolaou V, Dubos S, Athanassiou E, Tsezou A, Zacharia LC, Gkretsi V Tags: Clin Exp Metastasis Source Type: research

Expression distribution of cancer stem cells, epithelial to mesenchymal transition, and telomerase activity in breast cancer and their association with clinicopathologic characteristics.
Abstract A total of 167 surgically resected primary invasive breast carcinomas and 63 metastatic lymph node lesions were analyzed for immunohistochemical (IHC) localization of the CD44(+)CD24(-low) breast cancer stem cell (CSC) markers, epithelial to mesenchymal transition (EMT) markers, and telomerase activity by double-staining IHC technique, in formalin-fixed, paraffin-embedded tissue, the results were validated by double-staining immunofluorescent and flow cytometry techniques. The results showed that CSCs with CD44(+)CD24(-low) phenotype were significantly increased in node-positive tumors, high-grade tumors,...
Source: Clinical Breast Cancer - February 2, 2015 Category: Cancer & Oncology Authors: Makki J, Myint O, Wynn AA, Samsudin AT, John DV Tags: Clin Med Insights Pathol Source Type: research

Identification of a new BRCA2 large genomic deletion associated with high risk male breast cancer.
CONCLUSION: Large rearrangements in BRCA1 and BRCA2 occur in a small percentage (
Source: Clinical Breast Cancer - February 2, 2015 Category: Cancer & Oncology Authors: Timoteo AR, Albuquerque BM, Moura PC, Ramos CC, Agnez-Lima LF, Walsh T, King MC, Lajus TB Tags: Hered Cancer Clin Pract Source Type: research

HER2 and β-catenin protein location: importance in the prognosis of breast cancer patients and their correlation when breast cancer cells suffer stressful situations.
In conclusion, this study shows the dynamical associations of HER2 and β-catenin and their changes in subcellular localizations driven by stressful situations. In addition, we report for the first time the correlation between plasma membrane associated β-catenin in HER2-positive breast cancer and survival outcome, and the importance of the protein localization in breast cancer samples. PMID: 25636904 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 1, 2015 Category: Cancer & Oncology Authors: Cuello-Carrión FD, Shortrede JE, Alvarez-Olmedo D, Cayado-Gutiérrez N, Castro GN, Zoppino FC, Guerrero M, Martinis E, Wuilloud R, Gómez NN, Biaggio V, Orozco J, Gago FE, Ciocca LA, Fanelli MA, Ciocca DR Tags: Clin Exp Metastasis Source Type: research

[(18)F]Fluorodeoxyglucose PET/Computed Tomography in Breast Cancer and Gynecologic Cancers: A Literature Review.
en PT Abstract In this literature review, an update is provided on the role of [(18)F]fluorodeoxyglucose PET/computed tomography in different clinical settings of the 4 most frequent female-specific cancer types: breast, endometrial, ovarian, and cervical cancer. The most recent knowledge regarding primary diagnosis, staging, response evaluation, prognostic and predictive values, recurrence detection, and radiotherapy planning is evaluated, including, when clinically relevant, considerations with respect to the epidemiology, treatment, and course of the diseases. PMID: 25455882 [PubMed - as supplied by publis...
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Hildebrandt MG, Kodahl AR, Teilmann-Jørgensen D, Mogensen O, Jensen PT Tags: PET Clin Source Type: research

Effect of Paullinia cupana on MCF-7 breast cancer cell response to chemotherapeutic drugs.
DA Cruz IB Abstract Previous studies suggested that certain plants, such as guarana (Paullinia cupana), exert a protective effect against cancer-related fatigue in breast cancer patients undergoing chemotherapy. However, guarana possesses bioactive molecules, such as caffeine and catechin, which may affect the pharmacological properties of antitumor drugs. Therefore, the aim of this study was to evaluate the effects of guarana on breast cancer cell response to 7 chemotherapeutic agents currently used in the treatment of breast cancer. To perform this study, MCF-7 breast cancer cells were cultured under controlled ...
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Hertz E, Cadoná FC, Machado AK, Azzolin V, Holmrich S, Assmann C, Ledur P, Ribeiro EE, DE Souza Filho OC, Mânica-Cattani MF, DA Cruz IB Tags: Mol Clin Oncol Source Type: research

Assessment of health-related quality of life of patients with esophageal squamous cell carcinoma following esophagectomy using EORTC quality of life questionnaires.
Abstract Esophageal cancer is one of the leading causes of cancer-related mortality and surgery is currently the main treatment modality for resectable esophageal cancer. To assess health-related quality of life (HRQL) of patients with esophageal squamous cell carcinoma (ESCC) following esophagectomy, 62 consecutive patients with middle ESCC were randomly assigned into hand video-assisted thoracoscopic surgery (HVATS) (n=33) and Ivor-Lewis surgery (ILS) (n=29) groups. Quality of life questionnaires (QLQ)-C30 and QLQ-OES18, published by the European Organization for Research and Treatment of Cancer, were used prior...
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Shen O, Wang J, Li W, Yi W, Wang W Tags: Mol Clin Oncol Source Type: research

Potential risk factors for the development of seroma following mastectomy with axillary dissection.
In conclusion, the prediction of the development of seroma following mastectomy with axillary dissection is challenging. However, a longer operative time and the non-use of PCA may represent potential risk factors for this complication. PMID: 25469299 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Pan XF, Huan JL, Qin XJ Tags: Mol Clin Oncol Source Type: research

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer.
The objective of this study was to investigate the association of serum cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels with clinicopathological parameters in patients diagnosed with metastatic breast cancer (MBC). We retrospectively evaluated the medical records of 284 patients diagnosed with MBC between January, 2007 and December, 2012 who fulfilled the specified criteria and the association between the levels of the two tumor marker and clinicopathological parameters was analyzed. Of the 284 patients, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were identified in 163 (57.4%...
Source: Clinical Breast Cancer - December 7, 2014 Category: Cancer & Oncology Authors: Geng B, Liang MM, Ye XB, Zhao WY Tags: Mol Clin Oncol Source Type: research

Hypnotic relaxation therapy for reduction of hot flashes in postmenopausal women: examination of cortisol as a potential mediator.
Abstract Abstract Hypnotic relaxation therapy (HRT) has been shown to reduce hot flashes in postmenopausal women and breast cancer survivors. While the biological mechanism by which HRT reduces hot flashes is unknown, it has been speculated that reduction of stress mediates the intervention's effectiveness. The purpose of the present study was to examine the effect of HRT on a known biomarker of stress (cortisol) and changes in cortisol as a mediator. Sixty-two postmenopausal women received hypnotic relaxation therapy for hot flashes and completed measures of hot flashes in addition to providing cortisol samples a...
Source: Clinical Breast Cancer - November 10, 2014 Category: Cancer & Oncology Authors: Kendrick C, Johnson AK, Sliwinski J, Patterson V, Fisher WI, Elkins GR, Carpenter JS Tags: Int J Clin Exp Hypn Source Type: research

Emerging Modalities in Breast Cancer Imaging.
Abstract Breast cancer continues to be the most frequently diagnosed malignancy and the second leading cause of death caused by cancer in women in the United States. Although each of the emerging imaging techniques discussed in this article has advantages compared with standard mammography, they are not perfect, and each has inherent limitations. To date, none have been studied by large randomized clinical trials to match the proven benefits of screening mammography; namely the reduction of mortality caused by breast cancer by nearly 30%. PMID: 25246048 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Aminololama-Shakeri S, Khatri VP Tags: Surg Oncol Clin N Am Source Type: research

Quality measures: a call to action.
Abstract This supplement to the Clinical Journal of Oncology Nursing (CJON) marks a significant milestone in the sustained efforts of the Oncology Nursing Society (ONS) to improve the quality of cancer care-a core component of the ONS mission. The lead article by Fessele, Yendro, and Mallory on pages 7-11 of this supplement summarizes the ONS Foundation-supported Breast Cancer Care (BCC) and Breast Cancer Survivorship (BCS) Quality Measures project. ONS leaders recognized that efforts to improve performance and patient outcomes were limited by the lack of a core set of reliable and valid patient-centered measures....
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Beck SL Tags: Clin J Oncol Nurs Source Type: research

Setting the bar: developing quality measures and education programs to define evidence-based, patient-centered, high-quality care.
Abstract In 2008, the Oncology Nursing Society (ONS) initiated a multi-year project to develop and test quality measures in areas judged by oncology nurses as high-priority opportunities to improve quality of life for patients across the cancer continuum, and to provide education to oncology nurses on how to achieve high-quality care. Supported through a grant to the ONS Foundation by the Breast Cancer Fund of the National Philanthropic Trust, two teams of expert nurses convened to review the literature and draft potential measures that are considered important to providers and patients, are high-volume, high-impa...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Fessele K, Yendro S, Mallory G Tags: Clin J Oncol Nurs Source Type: research

The development of a nursing assessment and symptom management clinic.
Abstract The Anne Arundel Medical Center (AAMC) DeCesaris Cancer Institute (DCI) began its participation in the ONS Foundation-supported Breast Cancer Care Quality Measures Set pilot study in 2010. The design and measures of the project were intriguing, paving a path for DCI to define quality measures and outcomes that were of value to the AAMC's oncology population and system. As the pilot program was getting underway, measurement instruments were selected for fatigue, distress, and sleep-wake disturbances. These were used as quality measures for care of patients receiving chemotherapy, to be reported to the Onco...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Graze L, Brady-Copertino C, Varner A, Stiver WS Tags: Clin J Oncol Nurs Source Type: research

Impact of the breast cancer care measures pilot study on quality-improvement initiatives.
Abstract As a participant in the ONS Foundation-supported Breast Cancer Care Quality Measures Set in 2010, the Edward Cancer Center (ECC) identified gaps in patient assessment. Sleep-wake disturbance and distress were two common areas that were lacking consistent assessment when nurses saw patients during their visits. Another issue is the lack of standard methods of practice or a standardized tool. The ECC, in collaboration with Edward Diabetes Center, Linden Oaks Hospital, and other outpatient offices, adopted the use of the Patient Health Questionnaire-9 depression screening tool. The ECC also modified the inte...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: McGovern-Phalen AM Tags: Clin J Oncol Nurs Source Type: research

Improving cancer-related fatigue outcomes.
Abstract Participation in the ONS Foundation-supported Breast Cancer Care Quality Measures Set pilot study defined areas of need for compliance with proposed standards. Key outcomes were the revision of nursing assessment and documentation tools. Subsequent to those efforts, a walking track was made available for patients within the clinical cancer center. The track serves as an exercise resource for patients and family members to use while waiting for and after appointments. The planning involved multiple disciplines, and criteria established by the multidisciplinary team defined what group of patients should be ...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Griffie J, Godfroy J Tags: Clin J Oncol Nurs Source Type: research

Incorporating breast cancer care data into clinical assessment.
Abstract Participation in the ONS Foundation-supported Breast Cancer Care Quality Measures Set pilot study was an opportunity for staff at a National Cancer Institute-designated comprehensive cancer center to improve their process for introducing a change in practice. The institution's treatment area revised a documentation tool, and the medical practice area embarked on an education project based on evidence-based practice from the Oncology Nursing Society's Putting Evidence Into Practice initiative. After implementation, an increase in the number of patients being assessed for the quality measures of fatigue and...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: McAdams F, Martin V Tags: Clin J Oncol Nurs Source Type: research

Prospective protocol for lymphedema education and surveillance in a breast health center.
Abstract Participation in the ONS Foundation-supported Breast Cancer Survivorship Quality Measures Set pilot study indicated less than optimal assessment and educational practices for lymphedema surveillance at one author's institution. This finding led staff to expand on nursing practice associated with lymphatic dysfunction and to propose a surveillance tool that is easy to use in a busy clinical setting. Based on current trends in lymphatic surveillance, arm measurements were used to assess for relative percentage differences compared to baseline. The referral threshold for lymphedema diagnosis was set at a 10%...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Haley-Emery M, Schmitz-Johnson W Tags: Clin J Oncol Nurs Source Type: research

Managing late effects of breast cancer treatment.
This article illustrates the authors' participation in the ONS Foundation-supported Breast Cancer Survivorship (BCS) Quality Measures Set pilot study at Southern Ohio Medical Center (SOMC) Cancer Center. The data collection, outcomes, and action plans based on results are described. Included are the SOMC distress tool, psychosocial assessment tool, a survivorship care plan, and a clinical vignette describing how the tools and implementation of the action plan improved care and facilitated connection to supportive community resources. The BCS Measures pilot study provided a learning opportunity in identifying important qual...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Arnett J, Henry B, Fankell A Tags: Clin J Oncol Nurs Source Type: research

Implementation of an evidence-based education practice change for patients with cancer.
Abstract As oncology care continues to move toward delivery in the outpatient setting, oncology nurses must find ways to effectively educate patients about diagnosis, treatment, and symptom management. A cancer diagnosis induces high levels of anxiety, often affecting a patient's ability to retain information about his or her disease, treatment, and symptom management. Based on results from the ONS Foundation-supported Breast Cancer Care Quality Measures Set and Breast Cancer Survivorship Quality Measures Set, a community-based, multisite cancer center located in the midwestern United States embarked on a quality ...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Portz D, Johnston MP Tags: Clin J Oncol Nurs Source Type: research

Getting patients active: using national data to drive practice.
This article describes the barriers and challenges faced, in addition to the integration of exercise resources into patients' plans of care. The authors describe the curriculum for staff education regarding the practice change, implementation of an evidence-based fatigue assessment and interventions, and methods to integrate these resources into patient care. PMID: 25252992 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Scaramuzzo LA, Gordils-Perez J, Cullen PM Tags: Clin J Oncol Nurs Source Type: research

Improving psychosocial assessment in a community-based cancer center.
Abstract Numerous articles have demonstrated that patients undergoing treatment for cancer experience distress. Research has also shown that patients whose distress is effectively identified and treated may tolerate their chemotherapy better and have improved quality of life. Oncology nurses at the Lowell General Hospital Cancer Center, through their participation in the Breast Cancer Care Measures portion of the ONS Foundation-supported Breast Cancer Quality Measures Set pilot and the Oncology Quality Collaborative, identified that the distress assessment used at their institution was ineffective. The assessment ...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Huberty S, Buckley M Tags: Clin J Oncol Nurs Source Type: research

Paths to Partnership: Veterans Health Administration's Journey in Pilot Testing Breast Cancer Care Quality Measures.
Abstract Prioritizing personalized, proactive, patient-driven health care is among the Veterans Health Administration's (VHA's) transformational initiatives. As one of the largest integrated healthcare systems, the VHA sets standards for performance measures and outcomes achieved in quality of care. Evidence-based practice (EBP) is a hallmark in oncology nursing care. EBP can be linked to positive outcomes and improving quality that can be influenced directly by nursing interventions. VHA oncology nurses had the opportunity to partner with the Oncology Nursing Society (ONS), ONS Foundation, and the Joint Commissio...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Hogg LH Tags: Clin J Oncol Nurs Source Type: research

Development of a survivorship program.
This article provides the necessary steps for the development and implementation of an institution-specific survivorship program to fulfill the new standards for survivorship care. PMID: 25252995 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Downs-Holmes C, Dracon A, Svarovsky T, Sustin M Tags: Clin J Oncol Nurs Source Type: research

Measuring preoperative anxiety in patients with breast cancer using the visual analog scale.
Abstract Preoperative anxiety is a prevalent concern with deleterious effects in patient recovery and is not routinely assessed in the preoperative screening process. When it is assessed, it may prompt an increase in the use of anesthetic agents, heightened postoperative pain, and prolonged hospitalization. Preoperative women with breast cancer face anxiety as it relates to anesthesia, surgery, and recovery. The preoperative anxiety visual analog scale may identify and quantify anxiety in this population, provide advocacy and support, and improve the preoperative screening process. PMID: 25253102 [PubMed - in...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Aviado-Langer J Tags: Clin J Oncol Nurs Source Type: research

Accelerated partial breast irradiation.
Abstract Local therapies to treat newly diagnosed breast cancer include a lumpectomy with radiation therapy or a mastectomy. The 20-year data from studies about the safety and efficacy of lumpectomy with full-breast radiation therapy support the safety of this regimen and its role to decrease the risk of ipsilateral recurrence and increase long-term survivorship of women with breast cancer. Accelerated partial breast irradiation (APBI) provides radiation therapy to the tumor bed but spares the remaining breast tissue. APBI accelerates the time required to complete the therapy regimen, with a range of one intraoper...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Bauer E, Lester JL Tags: Clin J Oncol Nurs Source Type: research

Malignant phyllodes tumor of the breast: a case study.
This article includes pertinent clinical and age-specific considerations for comprehensive management. PMID: 25253115 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Keim-Malpass J, Mills AM, Showalter SL Tags: Clin J Oncol Nurs Source Type: research

Diagnosis and treatment of lymphedema in patients with breast cancer.
Abstract Lymphedema is a distressing consequence of breast cancer treatment affecting the patient in all domains of quality of life. Early identification and diagnosis are key to preventing long-term consequences. The goal of lymphedema management is to slow the progression and provide symptomatic relief to maintain quality of life. Preoperative education, intensive postoperative follow-up, and long-term survivorship care are important to minimize risk factors for developing lymphedema and to provide a mechanism for early detection, treatment, and patient self-care. An interdisciplinary approach, including nutriti...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: McCaulley L, Smith J Tags: Clin J Oncol Nurs Source Type: research

Comparative Study of the One-step Nucleic Acid Amplification Assay and Conventional Histological Examination for the Detection of Breast Cancer Sentinel Lymph Node Metastases.
Abstract Intraoperative sentinel lymph node (SLN) biopsy is widely used in patients with early-stage breast cancer and is conventionally performed using hematoxylin and eosin-based histological examination. The one-step nucleic acid amplification (OSNA) assay is a molecular diagnostic tool and a semi-automated lymph node examination method. The purpose of this study was to compare the performance of the OSNA assay and conventional histological examination with frozen sections (FSs) by using 111 SLN biopsy samples from 89 patients at the Tokai University Hospital. The SLN samples were split into 3 slices: the middl...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Terada M, Niikura N, Tsuda B, Masuda S, Kumaki N, Tang X, Okamura T, Saito Y, Suzuki Y, Tokuda Y Tags: Tokai J Exp Clin Med Source Type: research

Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information.
Abstract BACKGROUND: The St. Gallen International Expert Consensus of 2011 proposes a new classification system for breast cancer based on its division into five subgroups. The criteria to identify these subtypes were recently refined at the 2013 Conference. In this respect, the authors of this paper have conducted a retrospective analysis of breast cancer subtypes, related to Ki-67 and involvement of the axillary lymph nodes (ALNs). The analysis was performed only in the cases of invasive breast cancer in the pT2 stages. The research and results of the paper have shown that investigating the value of these parame...
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djurisic I, Inic I, Pupic G, Jancic S Tags: Clin Med Insights Oncol Source Type: research

Importance of presurgical breast MRI in patients 60 years of age and older.
CONCLUSIONS: Among the patients aged 60 years and above who had presurgical bilateral breast MRI, we found additional cancers in 9.0% (n = 114/1268) and atypia in 2.4% (n = 31/1268). A change in management as a result of the MRI-detected lesion occurred in 8.8% (n = 111/1268). These results demonstrate that performing presurgical bilateral breast MRI is of value in women 60 years of age and above. PMID: 25250195 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 29, 2014 Category: Cancer & Oncology Authors: Destounis SV, Arieno AL, Morgan RC Tags: J Clin Imaging Sci Source Type: research

Single photon emission computed tomography (SPECT) and SPECT/low-dose computerized tomography did not increase sensitivity or specificity compared to planar bone scintigraphy for detection of bone metastases in advanced breast cancer.
CONCLUSION: WBS, SPECT and SPECT/ldCT were less sensitive than MRI and equally specific for the detection of bone metastases in patients with advanced breast cancer. Based on our findings, we suggest that initial staging include WBS, MRI of the spine and CT for soft tissue evaluation. Further studies may clarify the potential benefits of whole-body MRI and 18F-NaF PET/CT or 18F-FDG PET/CT. PMID: 25257661 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 26, 2014 Category: Cancer & Oncology Authors: Haraldsen A, Bluhme H, Røhl L, Pedersen EM, Jensen AB, Hansen EB, Nellemann H, Rasmussen F, Morsing A Tags: Clin Physiol Funct Imaging Source Type: research

Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.
CONCLUSIONS: Population pharmacokinetics of ARS and DHA in patients with breast cancer was well described by a combined drug-metabolite model without any covariates and with an increase in apparent elimination clearance of DHA over time. The estimated DHA saliva/plasma ratio was in good agreement with the reported DHA unbound fraction in human plasma. Saliva ARS concentrations correlated poorly with plasma concentrations. This suggests the use of saliva sampling for therapeutic drug monitoring of DHA. However, further studies are warranted to investigate the robustness of this approach. PMID: 25248945 [PubMed - as sup...
Source: Clinical Breast Cancer - September 25, 2014 Category: Cancer & Oncology Authors: Ericsson T, Blank A, von Hagens C, Ashton M, Abelö A Tags: Eur J Clin Pharmacol Source Type: research

Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru.
J, Weitzel JN, Narod SA Abstract The prevalence of BRCA1 and BRCA2 mutations among breast cancer patients in Peru has not yet been explored. We enrolled 266 women with breast cancer from a National cancer hospital in Lima, Peru, unselected for age or family history. DNA was screened with a panel of 114 recurrent Hispanic BRCA mutations (HISPANEL). Among the 266 cases, thirteen deleterious mutations were identified (eleven in BRCA1 and two in BRCA2), representing 5% of the total. The average age of breast cancer in the mutation-positive cases was 44 years. BRCA1 185delAG represented seven of the eleven mutations in...
Source: Clinical Breast Cancer - September 25, 2014 Category: Cancer & Oncology Authors: Abugattas J, Llacuachaqui M, Sullcahuaman Allende Y, Arias Velásquez A, Velarde R, Cotrina J, Garcés M, León M, Calderón G, de la Cruz M, Mora P, Royer R, Herzog J, Weitzel JN, Narod SA Tags: Clin Genet Source Type: research

Effects of an aerobic exercise programme on fatigue for patients with breast cancer undergoing radiotherapy.
CONCLUSIONS: The mild- to moderate-intensity aerobic exercise programme reduces the fatigue of Taiwanese women with breast cancer undergoing radiotherapy. The issues of cancer-related fatigue should also be discussed as they relate to other treatment modalities. RELEVANCE TO CLINICAL PRACTICE: Aerobic exercise intervention should be offered as an option for women with breast cancer to alleviate cancer-related fatigue when undergoing radiotherapy. PMID: 25257238 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 25, 2014 Category: Cancer & Oncology Authors: Yang TY, Chen ML, Li CC Tags: J Clin Nurs Source Type: research

By the Numbers: Does Circulating Tumor Cell Enumeration Have a Role in Metastatic Breast Cancer?
PMID: 25245442 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 22, 2014 Category: Cancer & Oncology Authors: Liu MC Tags: J Clin Oncol Source Type: research

Recommendation for Omitting Axillary Lymph Node Dissection Should Be Individualized in Patients With Breast Cancer With One or Two Positive Sentinel Lymph Nodes.
PMID: 25245448 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 22, 2014 Category: Cancer & Oncology Authors: Voutsadakis IA, Spadafora S Tags: J Clin Oncol Source Type: research

Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: A single-center study in the United Arab Emirates.
CONCLUSION: This first decision impact study in a Middle Eastern country showed the significant effect of Oncotype DX testing on clinical practice, further demonstrating the consistent impact of such testing worldwide. PMID: 25243360 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 22, 2014 Category: Cancer & Oncology Authors: Jaafar H, Bashir MA, Taher A, Qawasmeh K, Jaloudi M Tags: Asia Pac J Clin Oncol Source Type: research

Patient-reported quality of life, unmet needs and care coordination outcomes: Moving toward targeted breast cancer survivorship care planning.
This study evaluated quality of life, unmet needs, satisfaction with health care and perception of cancer care coordination at the end of treatment in a cohort of women at the end of treatment for early breast cancer. The aim was to identify specific needs to assist in the design of a tailored SCP. METHODS: Women completed patient-reported measures of health-related quality of life (FACT-B [ES]), unmet needs (CaSUN), satisfaction with medical care and cancer care coordination. Total scores and subscale scores for the whole cohort and results of analysis comparing three age groups were reported. RESULTS: Sixty-eig...
Source: Clinical Breast Cancer - September 22, 2014 Category: Cancer & Oncology Authors: Brennan ME, Butow P, Spillane AJ, Boyle F Tags: Asia Pac J Clin Oncol Source Type: research

Biochemical evaluation of hyaluronic acid in breast cancer.
Abstract BACKGROUND: The latest experimental studies on human cancer diseases have observed the bioactive role of hyaluronic acid (HA) during carcinogenesis. HA is a component of the extra-cellular matrix (ECM). It is closely correlated with tumor cell growth, proliferation, and metastasis. The present study aimed to evaluate the biochemical role of HA and its degrading enzymes and products in breast cancer (BC) patients under therapy treatment. METHODS: An ELISA method was used to determine HA levels and standard spectrophotometric techniques were used to estimate the activities of HA degrading enzymes hyalu...
Source: Clinical Breast Cancer - September 19, 2014 Category: Cancer & Oncology Authors: Yahya RS, El-Bindary AA, El-Mezayen HA, Abdelmasseh HM, Eissa MA Tags: Clin Lab Source Type: research

Clinicopathological and prognostic significance of serum cytokine levels in breast cancer.
This study was designed to examine the serum levels of six cytokines (IFN-gamma, TNF-alpha, IL-2, IL-4, IL-5, and IL-10) in treated and untreated breast cancer patients and assess their clinical significance. The correlation of the Th1/Th2 type cytokine levels and the clinicopathologic variables was further evaluated. METHODS: Cytometric Bead Array (CBA) was used to examine the levels of Th1 cytokines (TNF-alpha, IFN-gamma, and IL-2) and Th2 cytokines (IL-4, IL-5, and IL-10) in serum of 36 untreated and 73 treated breast cancer patients and 51 healthy females as control. RESULTS: In the untreated group, the level...
Source: Clinical Breast Cancer - September 19, 2014 Category: Cancer & Oncology Authors: Zhu X, Du L, Feng J, Ling Y, Xu S Tags: Clin Lab Source Type: research

Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada.
CONCLUSIONS: PALB2 mutation screening identifies a small, but significant number of mutations in BRCA1/2 -negative breast and/or ovarian cancer families. We show that mutations are more likely to be found in families with three or more breast cancers as well as other BRCA2-related cancers. In our cohort, both clearly pathogenic mutations were identified in premenopausal breast cancer cases (2/77, 2.6%). Testing should be preferentially offered to affected women from such families. PMID: 25225577 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 19, 2014 Category: Cancer & Oncology Authors: Hartley T, Cavallone L, Sabbaghian N, Silva-Smith R, Hamel N, Aleynikova O, Smith E, Hastings V, Pinto P, Tischkowitz M, Tomiak E, Foulkes WD Tags: Hered Cancer Clin Pract Source Type: research

Cytokeratin 19, thyroperoxidase, HBME-1 and galectin-3 in evaluation of aggressive behavior of papillary thyroid carcinoma.
Abstract OBJECTIVE: To assess usefulness of cytokeratin 19 (CK19), thyroperoxidase (TPO), Hector Battifora mesothelial epitope-1 (HBME-1) and galectin-3 (GAL3) in evaluation of aggressive behavior of PTCs. METHODS: All available clinical and pathological data were reviewed in 168 papillary thyroid cancer patients; while the values as predictive markers of PTC were tested by univariate and multivariate analysis. RESULTS: According to the univariate set of tests, positive expression of CK19 and negative expression of TPO correlated significantly with total tumor diameter (P
Source: Clinical Breast Cancer - September 19, 2014 Category: Cancer & Oncology Authors: Liu Z, Li X, Shi L, Maimaiti Y, Chen T, Li Z, Wang S, Xiong Y, Guo H, He W, Liu C, Nie X, Zeng W, Huang T Tags: Int J Clin Exp Med Source Type: research

A case of mucoepidermoid carcinoma located in the left forearm of a middle-aged pregnant woman.
Abstract In this article, we described a mucoepidermoid carcinoma (MEC) located in the left forearm of a 39-year-old pregnant woman. Here, the patient had a superficial tip size apophysis nearly 3 years, which begin to sustained growth after pregnant in 2012, and stopped growth after childbirth. MEC is a rare malignant tumor. Previously reports showed it mainly arise from the salivary, bronchial, thyroid, breast, lacrimal gland and conjunctiva. Here, we reported a case of MEC arising from the forearm gland for the first time. Histological finding showed a cystic and solid tumor in fibrous tissue below the squamous...
Source: Clinical Breast Cancer - September 19, 2014 Category: Cancer & Oncology Authors: Liang YF, Lin XY, Ruan JB, Zeng JC, Kang DP, Wang LM, Chen C, Xu JF, Wu QL Tags: Int J Clin Exp Med Source Type: research

The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis.
CONCLUSIONS: These findings support the use of agonistic TRAIL antibodies and drugs targeting FLIP in breast cancer patients. Over-expression of FLIPT but not TRAIL-R1, TRAIL-R2 or FLIPL provides stage-independent prognostic information in breast cancer patients. This indicates a clinically less aggressive phenotype. PMID: 25230899 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 18, 2014 Category: Cancer & Oncology Authors: Ullenhag GJ, Al-Attar A, Mukherjee A, Green AR, Ellis IO, Durrant LG Tags: J Cancer Res Clin Oncol Source Type: research

Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models.
Abstract Purpose: Tumor cells are surrounded by a complex microenvironment. The purpose of our study was to evaluate the role of heterogeneity of the tumor microenvironment in the variability of nanoparticle (NP) delivery and efficacy. Experimental Design: C3(1)-T-Antigen genetically engineered mouse model (C3-TAg) and T11/TP53Null orthotopic syngeneic murine transplant model (T11) representing human breast tumor subtypes basal-like and claudin-low, respectively, were evaluated. For the pharmacokinetic studies, non-liposomal doxorubicin (NL-doxo) or polyethylene glycol tagged (PEGylated) liposomal doxorubicin (PLD...
Source: Clinical Breast Cancer - September 17, 2014 Category: Cancer & Oncology Authors: Song G, Darr D, Santos CM, Ross M, Valdivia A, Jordan J, Midkiff BR, Cohen SM, Feinberg NN, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC Tags: Clin Cancer Res Source Type: research

First-in-Human study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics and Pharmacodynamics, in Patients with Metastatic Cancer.
Conclusion: CH5132799 is well tolerated at the MTD dose 48 mg BID. At this dose the drug had a favorable PK and PD profile and preliminary evidence of clinical activity. PMID: 25231405 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - September 17, 2014 Category: Cancer & Oncology Authors: Blagden S, Omlin A, Josephs DH, Stavraka C, Zivi A, Pinato DJ, Anthoney DA, Decordova S, Swales K, Riisnaes R, Pope L, Noguchi K, Shiokawa R, Inatani M, Prince J, Jones K, Twelves CJ, Spicer JF, Banerji U Tags: Clin Cancer Res Source Type: research